Upadacitinib for Treatment-Resistant Urticarial Vasculitis: A Case Study and Therapeutic Insight

Upadacitinib for Treatment-Resistant Urticarial Vasculitis: A Case Study and Therapeutic Insight

Saved in:

Bibliographic Details
Main Authors:	Francesca Falcinelli, Edoardo Conticini, Luca Cantarini, Bruno Frediani, Pietro Rubegni, Laura Calabrese
Format:	Article
Language:	English
Published:	Mattioli1885 2025-04-01
Series:	Dermatology Practical & Conceptual
Subjects:	urticarial vasculitis upadacitinib jak-inhibitors Janus Kinase Inhibitors
Online Access:	https://dpcj.org/index.php/dpc/article/view/5139
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Case Report: Upadacitinib in the management of refractory urticarial vasculitis
by: Maan M. Almaghrabi, et al.
Published: (2025-08-01)

Refractory Chronic Hand Eczema Responds to Oral Upadacitinib
by: Nada Alghamdi, et al.
Published: (2025-01-01)

Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature
by: Li B, et al.
Published: (2025-05-01)

A case of psoriasis and atopic dermatitis-like rash induced by interleukin-17 and interleukin-23 inhibitors successfully controlled with upadacitinib
by: Toshiki Okazaki, MD, et al.
Published: (2025-09-01)

Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024-12-01)

Upadacitinib Monotherapy for Treatment of Pyoderma Gangrenosum
by: Mohamad R. Taha, et al.
Published: (2025-12-01)

Leukocytoclastic vasculitis in JAK2-positive essential thrombocythemia: a case of cytokine-driven urticarial rash responsive to ruxolitinib
by: Murad Aldarayseh, et al.
Published: (2025-07-01)

The use of selective Janus kinase inhibitor upadacitinib in a patient with psoriatic arthritis (clinical observation)
by: Yu. A. Lushpaeva
Published: (2025-04-01)

Case Report: Successful management of refractory palmoplantar pustulosis with upadacitinib
by: Boyun Yang, et al.
Published: (2025-03-01)

Treatment of eosinophilic annular erythema with upadacitinib
by: Wanyan Xiang, et al.
Published: (2025-12-01)

Treatment of Moderate-to-severe Atopic Dermatitis with Upadacitinib: Results from an Interim Analysis of the TREATgermany Registry
by: Barbara Kind, et al.
Published: (2025-05-01)

The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases
by: E. L. Nasonov, et al.
Published: (2020-11-01)

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study
by: Filip Van den Bosch, et al.
Published: (2025-02-01)

Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
by: Teppei Hagino, et al.
Published: (2024-12-01)

Potential role of upadacitinib in cytomegalovirus colitis recurrence
by: Kaito Tsujinaka, et al.
Published: (2025-04-01)

Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis
by: Diego Dominguez, et al.
Published: (2025-05-01)

Upadacitinib for the treatment of radiographic axial spondyloarthritis — case series and review of the literature
by: Giuseppe Lopalco, et al.
Published: (2025-05-01)

Vitiligo exacerbation during upadacitinib treatment for atopic dermatitis and improvement following a switch to abrocitinib: a case report
by: Zhaoyang Wang, et al.
Published: (2025-12-01)

Successful Treatment of Nail Lichen Planus by the Janus Kinase 1 Upadacitinib and Literature Review
by: Zhao X, et al.
Published: (2025-08-01)

Clinical observation of 10 cases of stable non-segmental vitiligo in adults treated with upadacitinib
by: Mingzhu Yuan, et al.
Published: (2025-12-01)

Case report: Effectiveness of Janus kinase inhibitors in the management of isolated noninfectious uveitis: a case series
by: Nina Vidic Krhlikar, et al.
Published: (2025-03-01)

Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?
by: Edoardo Mortato, et al.
Published: (2025-12-01)

Treatment of recalcitrant hypertrophic lichen planus with upadacitinib
by: Sabrina F. Schundler, BS, et al.
Published: (2025-05-01)

State-of-the-Art Evidence for Clinical Outcomes and Therapeutic Implications of Janus Kinase Inhibitors in Moderate-to-Severe Ulcerative Colitis: A Narrative Review
by: Yunseok Choi, et al.
Published: (2025-05-01)

Urticarial hypocomplementemic vasculitis syndrome and systemic lupus erythematosus: a case report and review of the literature
by: Yasmina Ouerdani, et al.
Published: (2025-08-01)

Efficacy and Safety of Upadacitinib and Vedolizumab Combination for Refractory Orofacial Granulomatosis Associated with Panenteric Crohn’s Disease: A Case Report
by: Michele Campigotto, et al.
Published: (2025-03-01)

Dual immunomodulator therapy with adalimumab and upadacitinib to treat recalcitrant hidradenitis suppurativa
by: Zahidul Islam, BA, et al.
Published: (2025-02-01)

Janus Kinase Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: A Review
by: Olimpia Wiciun, et al.
Published: (2025-05-01)

Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis
by: Rui Chai, et al.
Published: (2025-07-01)

JAK Inhibitor and Crohn’s Disease
by: Mengyan Xu, et al.
Published: (2025-05-01)

Livedoid Vasculopathy Successfully Treated With JAK Inhibitors
by: Antoine Delpuech, et al.
Published: (2025-06-01)

Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients
by: Na Du, et al.
Published: (2024-11-01)

Successful treatment of recalcitrant follicular lichen planus (lichen planopilaris) with the topical JAK 1/2 inhibitor ruxolitinib
by: Tanja Fetter, et al.
Published: (2025-03-01)

Modern Management Approaches for Alopecia Areata
by: Eduard T. Ambarchyan, et al.
Published: (2024-12-01)

Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysisCapsule Summary
by: Daniel Isufi, BSc(Med), et al.
Published: (2025-02-01)

Case report: Generalized granuloma annulare successfully treated with baricitinib in two cases
by: Marina Yunoki, et al.
Published: (2025-01-01)

Janus kinase inhibitors in the treatment of psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-02-01)

Favorable responses to upadacitinib, a JAK1 inhibitor, in long COVID patients with predominant neuropsychiatric symptoms: case reports in 2 autistic patients and one typically developing patient
by: Harumi Jyonouchi, et al.
Published: (2025-08-01)

Treatment with Upadacitinib in Difficult-to-Treat (D2T) Psoriatic Arthritis (PsA): A National Multicenter Study of the First 134 Patients in Clinical Practice
by: Eva Galíndez-Agirregoikoa, et al.
Published: (2025-05-01)

Advances in Topical Therapies for Clinically Relevant and Prevalent Forms of Alopecia
by: Aarushi K. Parikh, et al.
Published: (2024-12-01)